SLS Stock Hits July Low As AML Readout Nears — Retail Bulls See ‘Stellar’ Hint In CEO’s Fox Appearance Next Week

• The appearance fueled retail speculation that major clinical news could be close, though Sellas has not confirmed any data release.
• The Regal trial has reached 78 of the 80 events needed to trigger final analysis of GPS in AML patients.
• Stergiou said slower event accrual could reflect a durable GPS survival benefit, but Sellas remains blinded.

Shares of Sellas Life Sciences (SLS) fell to their lowest level so far this month as investors awaited a key readout from its acute myeloid leukemia (AML) trial, but CEO Angelos Stergiou’s upcoming Fox & Friends appearance has retail traders betting that major clinical news may be close.

SLS stock slid 8% on Thursday, logging its second straight session of losses. 

SLS Traders Eye Fox Appearance For Clinical Clues

In a LinkedIn post, Stergiou said that he would return to the program next week to discuss Sellas' "novel clinical developments" involving its lead drug candidates, GPS and SLS009. "We will surely be diving into SELLAS's novel clinical developments and paving the way for more personalized patient care with GPS & SLS009," he said.

The announcement quickly became a talking point among retail investors, many of whom questioned why Stergiou would schedule a national television appearance so close to one of the company's biggest catalysts. On Stocktwits, retail sentiment for SLS flipped to ‘bearish’ from ‘bullish’ levels a week ago amid a 60% jump in 24-hour message volumes.

"What CEO in their right mind would go on Fox News days/weeks before a major catalyst unless it's nothing short of stellar, game changing or fantastic news?" one trader said.

Another pointed to the timing, arguing Stergiou could have appeared after the trial reached 72 or 78 events if he simply wanted to discuss the delayed timeline. "Why next week all of a sudden?" the user said. "Pretty last minute, we will soon find out!"

Others focused on Stergiou's wording, saying that the phrase "novel clinical developments" meant previously undisclosed clinical findings rather than a routine corporate update. Sellas, however, has not indicated that any data will be released during the Fox appearance.

SLS Investors Await 80th Regal Event

The main catalyst for SLS investors remains Regal, the Phase 3 trial of galinpepimut-S, or GPS, in AML patients in second complete remission. The study has reached 78 of the 80 events required to trigger its final analysis. Sellas has said the trial would be considered successful if GPS extends median overall survival to 12.6 months, versus eight months for best available therapy.

Stergiou recently said that the company would announce the 80th event and then enter an official quiet period until topline results. This has fueled debate over whether the milestone and results could arrive separately or as one package. “Announcing the 80th alone buys you nothing,” one trader said. “You just tell the market, ‘We hit the trigger, results coming soon.’” The trader said that a combined announcement would suggest Sellas had already completed its analysis, adding: “You don’t go on Fox & Friends the same week you announce a trial failure.”

SLS CEO Defends Slower Regal Accrual

Stergiou also  pushed back against claims that the delayed 80th event means control-arm patients are living longer. “Let’s separate the noise from the data,” he wrote, arguing that slower accrual could instead signal a durable GPS benefit and a long-term survival “tail.” He cited GPS’ Phase 2 median overall survival of 21 months.

Sellas remains blinded, so the delay does not reveal which arm is driving the trend. Stergiou also opposed stopping at 78 events. “Events are our statistical currency,” he said, warning that an early halt could raise regulatory and timing-bias concerns.

The nearing readout has additionally revived retail speculation about a partnership or acquisition. Investors have cited Stergiou’s references to “strategic partners,” amended change-of-control benefits and Sellas’ surging valuation.

SLS stock has surged 512% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: ASTS Stock Hits 2026 Low After Surprise $1B Raise — But Jon Najarian Calls It A ‘Strong Bet To The Upside’